ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY

Introduction: Peripheral T-cell lymphomas (PTCL) are a rare disease with a poor prognosis, even when treated with high dose chemotherapy and stem cell transplantation (HDC + SCT). Romidepsin (Ro), a histone deacetylase inhibitor, showed activity in relapsed or refractory PTCLs, with a good profile of safety. Methods: In the phase Ib FIL-PTCL13 (NCT02223208), we tested the combination of Ro with cyclophosphamide, doxorubicin, etoposide,...